Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

IBS patients treated with cognitive behavior therapy have positive response: Study

A significant proportion of irritable bowel syndrome patients treated with cognitive behavior therapy have a positive response within four weeks of treatment, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

27 Apr 2010

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases in the global marketplace in collaboration with local partners, is pleased to announce the formation of a Finder's Agreement with its licensee for crofelemer in China, Luye Pharma Group Ltd. (formerly Asiapharm).

26 Apr 2010

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Salix Pharmaceuticals, Ltd. today announced that the Company will host a DDW2010 Investor Event on Monday, May 3 2010 from 9:00 p.m. to 10:00 p.m. Central Time (10:00 p.m. to 11:00 p.m. ET).

22 Apr 2010

Homeopathy – Is it a safer and effective alternative?

Studies have shown that nearly 45% Britons rely on Homeopathy, a branch of medicine that has been doubted by many and loved by an equal number.

20 Apr 2010

Research roundup: Revamping NCI Clinical Trials, reducing malpractice suits, health disparities persist

A National Cancer Clinical Trials System For The 21st Century: Reinvigorating The NCI Cooperative Group Program - The "system for conducting cancer clinical trials in the United States is approaching a state of crisis," according to this report on inefficiencies and funding issues faced by the NCI's Clinical Trials Cooperative Group Program - which comprises 10 groups, more than 3,100 institutions, 14,000 investigators and more than 25,000 patients in clinical trials each year.

17 Apr 2010

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

Ocera Therapeutics, Inc. presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients. The data came from the screening period of the ASTUTE Study, an ongoing Phase 2b study evaluating the safety and efficacy of AST-120 (spherical carbon adsorbent) in the treatment of mild hepatic encephalopathy (MHE). The poster was presented yesterday at the annual meeting of the European Association for the Study of Liver (EASL) in Vienna, Austria. Efficacy and safety data from the ASTUTE study are expected in the summer of 2010.

17 Apr 2010

S. thermophilus CRL 1190-fermented milk effective in therapeutic treatment of chronic gastritis: Research

Gastritis produced by acetyl-salicylic acid consumption is a common disorder worldwide. The use of probiotics has been proposed to ameliorate different gastrointestinal tract diseases such as inflammatory bowel disease, diarrhea, irritable bowel syndrome, etc. However, little attention has been paid to the use of probiotics in gastric disease.

12 Apr 2010

EndoChoice announces acquisition of Pathworks Anatomic Pathology Laboratory

EndoChoice, Inc. announced today that it has acquired Pathworks Anatomic Pathology Laboratory. Founded in 1989, Pathworks is a College of American Pathologists (CAP) accredited national reference laboratory located in Atlanta, GA. Robert Smith, MD, founder of the laboratory, will assume the Medical Director position of EndoChoice Pathology, a wholly-owned subsidiary of EndoChoice, Inc.

8 Apr 2010

Rome Foundation develops Diagnostic Algorithms to diagnose GI symptoms

New clinical algorithms will give physicians a practical, efficient and cost-effective aid to diagnose the frequent gastrointestinal symptoms that patients commonly bring to their primary care doctors and gastroenterologists--symptoms of functional GI disorders that are often difficult to diagnose.

7 Apr 2010

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Cryo-Cell International, Inc. today announced results of a study published this month in the cover article of Stem Cells and Development showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders.

5 Apr 2010

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Side effects may limit use of Prometheus's Lotronex for IBS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.

5 Apr 2010

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.

5 Apr 2010

Gastrointestinal tract disorders GERD and IBS interlinked

Gastroesophageal reflux disorder (GERD) and irritable bowel syndrome (IBS) are two very common disorders affecting the gastrointestinal tract. About 10% of the population experience daily discomfort from reflux of gastric contents into the esophagus. More than 10% of the population experience abdominal pain and disturbed bowel movement because of irritable bowel syndrome.

2 Apr 2010

2010 DDW conference to highlight breakthrough research on GI health

Thousands of physicians, researchers and academics from around the world will gather in New Orleans in early May for Digestive Disease Week- (DDW-), the premiere scientific conference in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

2 Apr 2010

Mayo Clinic introduces a reliable and easy-to-understand resource on alternative medicine

Want to find ways that may help prevent illness naturally, for a fraction of the cost of a trip to the doctor? Interested in taking control of your health with evidence-based practices that complement conventional medicine?

2 Apr 2010

Vidazorb probiotic supplements could minimize severity of IBS symptoms

April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.

31 Mar 2010

Renowned expert to present latest research on gut microbes at EICC

Trillions and trillions of bacteria live in the human gut. The thought of all these invisible inhabitants inside you might be yucky, but without them we would not be here at all. Which microbes reside in our gut? Are they harmful? Where do they come from? What do they actually do deep in our bowels? Do pre- or pro- biotics affect them?

25 Mar 2010

Colorectal cancer survivor shares her experience

For Hempstead resident Lynette Love, mother of four and grandmother of five, surviving colorectal cancer took courage, diligence and faith. Now a 3-year survivor, Love is giving the love back to the community through her participation in the Sprint for Colorectal Oncology Prevention and Education (SCOPE) run.

25 Mar 2010

Lexicon Pharmaceuticals completes public offering and concurrent private placement of common stock

Lexicon Pharmaceuticals, Inc. today announced the completion of its previously-announced public offering and concurrent private placement of its common stock, resulting in net proceeds to Lexicon of approximately $181.4 million after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares.

20 Mar 2010

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

IBS patients treated with cognitive behavior therapy have positive response: Study

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Homeopathy – Is it a safer and effective alternative?

Research roundup: Revamping NCI Clinical Trials, reducing malpractice suits, health disparities persist

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

S. thermophilus CRL 1190-fermented milk effective in therapeutic treatment of chronic gastritis: Research

EndoChoice announces acquisition of Pathworks Anatomic Pathology Laboratory

Rome Foundation develops Diagnostic Algorithms to diagnose GI symptoms

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Side effects may limit use of Prometheus's Lotronex for IBS

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Gastrointestinal tract disorders GERD and IBS interlinked

2010 DDW conference to highlight breakthrough research on GI health

Mayo Clinic introduces a reliable and easy-to-understand resource on alternative medicine

Vidazorb probiotic supplements could minimize severity of IBS symptoms

Renowned expert to present latest research on gut microbes at EICC

Colorectal cancer survivor shares her experience

Lexicon Pharmaceuticals completes public offering and concurrent private placement of common stock

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in